Glorritus Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 6 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -16.08%
- Profit Growth 121.06%
- Ebitda 131.36%
- Net Worth 26.43%
- Total Assets 38.50%
About Glorritus Pharmaceuticals
Glorritus Pharmaceuticals Private Limited (GPPL) is a Private Limited Indian Non-Government Company incorporated in India on 02 January 2019 (Six years and one month 11 days old ). Its registered office is in Kozhikode, Kerala, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Manilal Manaikudath, Kuyil Chandran, Valiya Sunilkumar, and Two other members serve as directors at the Company.
Company Details
-
Location
Kozhikode, Kerala, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U33209KL2019PTC056158
-
Company No.
056158
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
02 Jan 2019
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Ernakulam
Industry
Who are the key members and board of directors at Glorritus Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pulikkal Beljith
|
Managing Director | 10-Jan-2020 | Current |
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Manilal Manaikudath
|
Director | 10-Jan-2020 | Current |
|
Kuyil Chandran
|
Director | 02-Jan-2019 | Current |
|
Valiya Sunilkumar
|
Director | 02-Jan-2019 | Current |
|
Manoharan Ajith
|
Director | 10-Jan-2020 | Current |
Financial Performance of Glorritus Pharmaceuticals.
Glorritus Pharmaceuticals Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 16.08% decrease. The company also saw a substantial improvement in profitability, with a 121.06% increase in profit. The company's net worth Soared by an impressive increase of 26.43%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Glorritus Pharmaceuticals?
In 2021, Glorritus Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Glorritus Pharmaceuticals?
Unlock and access historical data on people associated with Glorritus Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Glorritus Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Glorritus Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.